Pazdan Christopher 4

4 · KORU Medical Systems, Inc. · Filed Mar 18, 2026

AI-generated summary of this filing

Updated Mar 18, 2026

KORU Medical (KRMD) COO Christopher Pazdan Exercises Derivatives, Receives RSU Awards

What Happened

Christopher Pazdan, Chief Operating Officer of KORU Medical Systems (KRMD), exercised/converted 5,064 derivative units on 2026-03-16 (exercise price reported $0) and had 1,628 shares withheld to satisfy tax obligations (disposed) at $4.28 per share for a tax withholding value of $6,968. On 2026-03-17 he was granted three restricted stock unit (RSU) awards totaling 109,381 units (31,226 + 31,226 + 46,929), all reported as acquisitions at $0 (derivative awards).

Key Details

Transaction dates and prices:
- 2026-03-16: Exercise/conversion (code M) — 5,064 shares @ $0.00.
- 2026-03-16: Tax withholding (code F) — 1,628 shares withheld @ $4.28 → $6,968.
- 2026-03-17: Grants/awards (code A) — RSU awards of 31,226; 31,226; and 46,929 shares @ $0.00.
Shares owned after the transactions: not specified in the filing.
Notable footnotes:
- F1/F3: RSUs represent contingent rights to receive one share per unit upon vesting.
- F2: The 1,628-share disposition reflects shares withheld to satisfy tax obligations on vesting.
- F4: One RSU award is under the 2024 Omnibus Equity Incentive Plan and vests in equal increments beginning March 17, 2027 and on successive anniversaries.
- F5: Some units are performance-based (payable 0–150% of target depending on results as of 12/31/2028) and vest at 100% on a change in control before that date.
Filing timeliness: Form 4 was filed on 2026-03-18 for transactions dated 2026-03-16 and 03-17 (appears timely under Section 16 reporting deadlines).

Context

The exercise/conversion was recorded at $0 and the subsequent withholding indicates shares were used to cover tax liabilities rather than a cash sale of stock for proceeds to Mr. Pazdan.
Grants (RSUs) are awards that vest in the future (time- and/or performance-based); they do not represent immediately tradable shares until vesting and settlement occur.
These entries are routine insider equity compensation reporting; they document compensation-related exercises and awards rather than an open-market purchase or sale that would signal a direct buy/sell opinion.

Form 4

Period: 2026-03-16

Chief Operating Officer

Transactions

Exercise/Conversion
Common Stock
[F1]
2026-03-16+5,064→ 5,064 total
Tax Payment
Common Stock
[F2]
2026-03-16$4.28/sh−1,628$6,968→ 3,436 total
Award
Restricted Stock Unit
[F3][F4]
2026-03-17+31,226→ 31,226 total
→ Common Stock (31,226 underlying)
Award
Performance Stock Unit
[F3][F5]
2026-03-17+31,226→ 31,226 total
→ Common Stock (31,226 underlying)
Award
Option to buy Common Stock
[F4]
2026-03-17+46,929→ 46,929 total
Exercise: $4.35Exp: 2036-03-17→ Common Stock (46,929 underlying)

Footnotes (5)

[F1]Represents common stock issued upon vesting of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of common stock upon vesting.
[F2]Represents shares withheld to satisfy tax obligations upon vesting of restricted stock units.
[F3]Each unit represents a right to receive one share of common stock underlying the vested award on the applicable vesting date.
[F4]This restricted stock unit award was granted under the Issuer's 2024 Omnibus Equity Incentive Plan. The units comprising the award vest in equal increments on March 17, 2027 and each first, second and third anniversaries thereof (each, a vesting date).
[F5]These units will vest based upon the achievement of certain performance conditions as of December 31, 2028. The amount reported represents the amount of shares payable at target performance; the Reporting Person could earn 0%-150% of the amount reported depending on the level of performance achieved. These units will vest at 100% of the amount reported upon a change in control of the Company prior to December 31, 2028.

Signature

/s/ Thomas Adams - Attorney-in-Fact|2026-03-18

1 file